MRNA Can't Capitalize on COVID-19 Vaccine Update

Reports that the White House could fast-track a competitor's vaccine is putting pressure on MRNA today

Digital Content Manager
Aug 24, 2020 at 10:02 AM
facebook twitter linkedin

Moderna Inc (NASDAQ:MRNA) is slipping lower this morning, down 1.9% at $62.50, despite an announcement from the biotech that enrollment levels for its late-stage 30,000-patient COVID-19 vaccine trial have exceeded 40% -- along with a potential deal with the European Union (EU). Reports that the White House could be fast tracking AstraZeneca's COVID-19 vaccine candidate could be putting pressure on MRNA today. 

From a technical standpoint,  it appears the stock's 10-day moving average has emerged as a ceiling on the charts, coming in shortly after MRNA's all-time high of $95.21 late last month. The security is losing its footing near its recently supportive 80-day moving average too, though the shares still boast a roughly 239% lead for the year. 

The brokerage bunch seems to be holding out hope for a rebound. Just three of the 13 in coverage call it a "hold," compared to 10 "buy" or better ratings. Plus, the consensus 12-month price target of $93.62 is a 40.9% premium to Friday's close. 

Option players, however, have begun changing their tune. While calls still outnumber puts at an overall basis, MRNA's 10-day put/call volume ratio of 0.53 at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) stands higher than 91% of readings from the past year. 

Short sellers are taking interest in MRNA, too. In the last reporting period, short interest rose 10%. Now, the 27.19 million shares sold short make up 8.7% of Moderna's available float. 




If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Stock Pick Report


Special Offers from Schaeffer's Trading Partners